Clinical Trials | December 23, 2025
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Subscribe To Our Newsletter & Stay Updated
